Definium tees up regulatory submission for psychedelic on Phase III hat trick

Pharmaceutical Technology | Sep 15, 2026 6:04 AM EDT

Definium Therapeutics plans to submit an NDA for LSD-based psychedelic, DT120 in generalised anxiety disorder (GAD) during H1 2027.